Interaction Checker

Interacciones de Metilnaltrexona

Metilnaltrexona (Relistor), antagonista opioide, tiene 52 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 43; moderadas: 2; leves: 0; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 7. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (43)

  • Alvimopánantagonista opioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Belladona y opioopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Bictegravir, emtricitabina y tenofovir alafenamidaantirretroviralGrave

    Opioid Antagonist: Naloxegol ↑ naloxegol Avoid use with BIXLENVO; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (etiqueta de Bictegravir, emtricitabina y tenofovir alafenamida, Interacciones medicamentosas)

  • BuprenorfinaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Buprenorfina y naloxonaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Butalbital, ácido acetilsalicílico, cafeína y codeínabarbitúricoGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Butalbital, paracetamol, cafeína y codeínabarbitúricoGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • ButorfanolopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • CodeínaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • DarunavirantirretroviralGrave

    John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir… (etiqueta de Darunavir, Contraindicaciones)

  • Darunavir y cobicistatantirretroviralGrave

    John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is… (etiqueta de Darunavir y cobicistat, Contraindicaciones)

  • EluxadolinaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • FentaniloopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • HidrocodonaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Hidrocodona e ibuprofenoopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Hidrocodona y clorfenaminaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Hidrocodona y homatropinaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Hidrocodona y paracetamolopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • HidromorfonaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • LenacapavirantirretroviralGrave

    Opioid Antagonist: naloxegol ↑ naloxegol Avoid use with SUNLENCA; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (etiqueta de Lenacapavir, Interacciones medicamentosas)

  • LevorfanolopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • MetadonaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • MorfinaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • NalbufinaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Naldemedinaantagonista opioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Nalmefenoantagonista opioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Naloxegolantagonista opioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Naloxonaantagonista opioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Naltrexonaantagonista opioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Naltrexona y bupropiónantagonista opioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Nirmatrelvir y ritonavirantiviralGrave

    …Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists: finerenone • Non-opioid analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin… (etiqueta de Nirmatrelvir y ritonavir, Contraindicaciones)

  • OliceridinaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • OxicodonaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Oxicodona y paracetamolopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • OximorfonaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Paracetamol y codeínaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Pentazocina y naloxonaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Petidina (meperidina)opioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Prometazina y codeínaopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • RemifentaniloopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • TapentadolopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • TramadolopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Tramadol y paracetamolopioideGrave

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

Interacciones moderadas (2)

  • EtravirinaantirretroviralModerada

    Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (etiqueta de Etravirina, Interacciones medicamentosas)

  • Lofexidinaagonista alfa-adrenérgicoModerada

    Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (etiqueta de Lofexidina, Interacciones medicamentosas)

Sin interacción significativa según la etiqueta (7)

  • AcamprosatoSin interacción

    The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology ( 12.3 ) ]. (etiqueta de Acamprosato, Interacciones medicamentosas)

  • Bromfeniramina, pseudoefedrina y dextrometorfanoantihistamínicoSin interacción

    Drugs Metabolized by Cytochrome P450 Isozymes In healthy subjects, a subcutaneous dose of 0.3 mg/kg of RELISTOR did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Dextrometorfanofármaco serotoninérgicoSin interacción

    Drugs Metabolized by Cytochrome P450 Isozymes In healthy subjects, a subcutaneous dose of 0.3 mg/kg of RELISTOR did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Dextrometorfano y quinidinafármaco serotoninérgicoSin interacción

    Drugs Metabolized by Cytochrome P450 Isozymes In healthy subjects, a subcutaneous dose of 0.3 mg/kg of RELISTOR did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

  • Elvitegravir, cobicistat, emtricitabina y tenofovirantirretroviralSin interacción

    Narcotic Analgesics: buprenorphine/ naloxone ↑ buprenorphine ↑ norbuprenorphine ↓ naloxone No dosage adjustment of buprenorphine/naloxone is required upon coadministration with GENVOYA. (etiqueta de Elvitegravir, cobicistat, emtricitabina y tenofovir, Interacciones medicamentosas)

  • Emtricitabina y tenofovirantirretroviralSin interacción

    No clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline. (etiqueta de Emtricitabina y tenofovir, Interacciones medicamentosas)

  • Prometazina y dextrometorfanoantihistamínicoSin interacción

    Drugs Metabolized by Cytochrome P450 Isozymes In healthy subjects, a subcutaneous dose of 0.3 mg/kg of RELISTOR did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)

Compruebe Metilnaltrexona frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.